Jasper Therapeutics Stock Price To Earning

JSPRW Stock

USD 0.20 0.01 5.26%

Jasper Therapeutics fundamentals help investors to digest information that contributes to Jasper Therapeutics' financial success or failures. It also enables traders to predict the movement of Jasper Stock. The fundamental analysis module provides a way to measure Jasper Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jasper Therapeutics stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Jasper Therapeutics Company Price To Earning Analysis

Jasper Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Jasper Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Jasper Therapeutics is extremely important. It helps to project a fair market value of Jasper Stock properly, considering its historical fundamentals such as Price To Earning. Since Jasper Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jasper Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jasper Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Capital Surpluse	Total Liab	Long Term Investments	Total Current Assets	Common Stock	Long Term Debt	Net Receivables	Long Term Debt Total	Net Invested Capital	Capital Stock	Net Working Capital	Current Deferred Revenue	Short Term Debt
Total Assets		0.83	-0.78	-0.96	-0.81	0.98	-0.53	0.77	0.29	0.7	1.0	-0.7	-0.53	-0.74	-0.53	0.97	0.58	1.0	-0.53	0.66
Total Stockholder Equity	0.83		-0.59	-0.9	-0.73	0.73	-0.68	0.38	-0.18	0.69	0.84	-0.39	-0.68	-0.7	-0.68	0.82	0.45	0.83	-0.68	0.66
Net Tangible Assets	-0.78	-0.59		0.8	0.96	-0.86	0.76	-0.89	-0.63	-0.77	-0.75	0.97	0.76	0.71	0.76	-0.85	-0.49	-0.82	0.76	-0.82
Net Debt	-0.96	-0.9	0.8		0.84	-0.93	0.72	-0.66	-0.23	-0.77	-0.96	0.68	0.72	0.81	0.72	-0.92	-0.48	-0.97	0.72	-0.66
Retained Earnings	-0.81	-0.73	0.96	0.84		-0.85	0.81	-0.81	-0.39	-0.86	-0.79	0.87	0.81	0.78	0.81	-0.89	-0.46	-0.83	0.81	-0.94
Accounts Payable	0.98	0.73	-0.86	-0.93	-0.85		-0.55	0.87	0.48	0.71	0.97	-0.82	-0.55	-0.75	-0.55	0.96	0.56	0.98	-0.55	0.67
Short Term Investments	-0.53	-0.68	0.76	0.72	0.81	-0.55		-0.39	-0.19	-0.85	-0.53	0.63	1.0	0.77	1.0	-0.57	-0.07	-0.58	1.0	-0.73
Capital Surpluse	0.77	0.38	-0.89	-0.66	-0.81	0.87	-0.39		0.74	0.56	0.74	-0.94	-0.39	-0.53	-0.39	0.84	0.6	0.78	-0.39	0.69
Total Liab	0.29	-0.18	-0.63	-0.23	-0.39	0.48	-0.19	0.74		0.2	0.26	-0.79	-0.19	-0.2	-0.19	0.33	0.25	0.34	-0.19	0.19
Long Term Investments	0.7	0.69	-0.77	-0.77	-0.86	0.71	-0.85	0.56	0.2		0.7	-0.66	-0.85	-0.97	-0.85	0.7	-0.01	0.7	-0.85	0.83
Total Current Assets	1.0	0.84	-0.75	-0.96	-0.79	0.97	-0.53	0.74	0.26	0.7		-0.66	-0.53	-0.75	-0.53	0.96	0.55	0.99	-0.53	0.63
Common Stock	-0.7	-0.39	0.97	0.68	0.87	-0.82	0.63	-0.94	-0.79	-0.66	-0.66		0.63	0.61	0.63	-0.77	-0.46	-0.73	0.63	-0.72
Long Term Debt	-0.53	-0.68	0.76	0.72	0.81	-0.55	1.0	-0.39	-0.19	-0.85	-0.53	0.63		0.77	1.0	-0.57	-0.07	-0.58	1.0	-0.73
Net Receivables	-0.74	-0.7	0.71	0.81	0.78	-0.75	0.77	-0.53	-0.2	-0.97	-0.75	0.61	0.77		0.77	-0.69	0.06	-0.74	0.77	-0.7
Long Term Debt Total	-0.53	-0.68	0.76	0.72	0.81	-0.55	1.0	-0.39	-0.19	-0.85	-0.53	0.63	1.0	0.77		-0.57	-0.07	-0.58	1.0	-0.73
Net Invested Capital	0.97	0.82	-0.85	-0.92	-0.89	0.96	-0.57	0.84	0.33	0.7	0.96	-0.77	-0.57	-0.69	-0.57		0.68	0.97	-0.57	0.78
Capital Stock	0.58	0.45	-0.49	-0.48	-0.46	0.56	-0.07	0.6	0.25	-0.01	0.55	-0.46	-0.07	0.06	-0.07	0.68		0.59	-0.07	0.36
Net Working Capital	1.0	0.83	-0.82	-0.97	-0.83	0.98	-0.58	0.78	0.34	0.7	0.99	-0.73	-0.58	-0.74	-0.58	0.97	0.59		-0.58	0.65
Current Deferred Revenue	-0.53	-0.68	0.76	0.72	0.81	-0.55	1.0	-0.39	-0.19	-0.85	-0.53	0.63	1.0	0.77	1.0	-0.57	-0.07	-0.58		-0.73
Short Term Debt	0.66	0.66	-0.82	-0.66	-0.94	0.67	-0.73	0.69	0.19	0.83	0.63	-0.72	-0.73	-0.7	-0.73	0.78	0.36	0.65	-0.73

Click cells to compare fundamentals

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Competition

Predict Jasper Therapeutics

Jasper Retained Earnings

Retained Earnings

(161.12 Million)

Jasper Therapeutics reported Retained Earnings of (169.6 Million) in 2023

Based on the latest financial disclosure, Jasper Therapeutics has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.0% higher than that of the company.

Did you try this?

Run ETF Categories Now

ETF Categories

List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments

All Next

Launch Module

Jasper Fundamentals

	Return On Equity	-0.71
	Return On Asset	-0.41
	Number Of Shares Shorted	16.36 K
	EBITDA	(64.98 M)
	Net Income	(64.47 M)
	Cash And Equivalents	16.76 M
	Cash Per Share	1.65 X
	Total Debt	2.79 M
	Debt To Equity	0.22 %
	Current Ratio	1.96 X
	Book Value Per Share	5.58 X
	Cash Flow From Operations	(52.07 M)
	Earnings Per Share	(3.84) X
	Number Of Employees	45
	Beta	2.2
	Total Asset	94.89 M
	Retained Earnings	(169.6 M)
	Working Capital	76.56 M
	Net Asset	94.89 M

About Jasper Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Jasper Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC